Nuvalent的 zidesamtinib 显示在治疗高级肺癌方面前景光明, Nuvalent's zidesamtinib shows promise in treating advanced lung cancer, with FDA fast-tracking its review.

Nuvalent从ARROS-1试验中提供了大有希望的数据,该试验涉及Zidesamtinib,这是一种新药物,用于治疗以前使用过TKTI的病人的先进ROS1呈阳性的非小型细胞肺癌。 Nuvalent presented promising data from its ARROS-1 trial for zidesamtinib, a new drug for treating advanced ROS1-positive non-small cell lung cancer in patients who have previously used TKIs. 该药物显示出高效和安全性,FDA在实时瘤学审查计划下接受了新药申请. The drug showed high efficacy and safety, with the FDA accepting the New Drug Application under its Real-Time Oncology Review program. 这可能导致为这一病人群体提前批准zidesamtinib。 This could lead to earlier approval of zidesamtinib for this patient group.